eFT-508 (eFT508)
10mM in DMSO
- Product Code: 186868
CAS:
1849590-01-7
| Molecular Weight: | 340.38 g./mol | Molecular Formula: | C₁₇H₂₀N₆O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
eFT-508 is a selective inhibitor of MNK1 and MNK2 kinases, which play a key role in regulating protein synthesis in cancer cells through phosphorylation of the eukaryotic initiation factor 4E (eIF4E). By blocking this pathway, eFT-508 reduces the expression of oncoproteins such as c-Myc, cyclin D1, and Bcl-2, which are involved in tumor growth and survival. It is primarily investigated for its potential in cancer immunotherapy, where it enhances anti-tumor immune responses by increasing the production of pro-inflammatory cytokines and improving T-cell function. eFT-508 has shown synergistic effects when combined with immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies in preclinical models, making it a promising candidate for combination therapies in solid tumors and hematologic malignancies. Its application is focused on advancing treatments for cancers resistant to current immunotherapies.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿6,480.00 |
+
-
|
eFT-508 (eFT508)
eFT-508 is a selective inhibitor of MNK1 and MNK2 kinases, which play a key role in regulating protein synthesis in cancer cells through phosphorylation of the eukaryotic initiation factor 4E (eIF4E). By blocking this pathway, eFT-508 reduces the expression of oncoproteins such as c-Myc, cyclin D1, and Bcl-2, which are involved in tumor growth and survival. It is primarily investigated for its potential in cancer immunotherapy, where it enhances anti-tumor immune responses by increasing the production of pro-inflammatory cytokines and improving T-cell function. eFT-508 has shown synergistic effects when combined with immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies in preclinical models, making it a promising candidate for combination therapies in solid tumors and hematologic malignancies. Its application is focused on advancing treatments for cancers resistant to current immunotherapies.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :